A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
Open accessAbstract
BACKGROUND: AST1306 is an orally active irreversible small molecule inhibitor of EGFR (erbB1), HER2 (erbB2) and HER4 (erbB4) signaling. This is a phase I, open-label, dose-escalation study to evaluate the safety and tolerability, pharmacokinetics (PK), and preliminary anti-tumor effects of oral AST1306. In addition the effects of food on PK was tested. METHODS: A modified Fibonacci 3 plus 3 dose-escalation design was employed to determine the dose-limiting toxicity (DLT) and recommended phase II dose (RP2D) in patients with advanced solid tumors. The following dose levels were investigated: once daily (QD) at two dose levels (400-and 800 mg), twice daily (BID) in five dose levels (600-, 800-, 1000-, 1200- and 1500 mg), and three times daily (TID) in three dose levels (800-, 1000- and 1200 mg). In the PK and extension study, at least eight patients per dose cohort in three dose levels (maximum tolerated dose [MTD], one or two doses level lower than the MTD) were enrolled to evaluate the PK profiles. RESULTS: Seventy-one patients were enrolled, with breast (n = 22) and lung cancers (n = 14) being the most common primary cancers. The most frequent drug-related adverse events were grade 1 to 3 diarrhea and rash, grade 1 to 2 fatigue. During dose escalation, the key DLT was grade 3 diarrhea observed in 5 patients at 1000 mg BID (n = 1), 1500 mg BID (n = 1), 800 mg TID (n = 1) and 1200 mg TID (n = 2). AST1306 was rapidly absorbed and had moderate to high clearance. PK concentration parameters increased with dose over the range evaluated, with no evidence of accumulation over time. Under fed conditions, the mean T(max) was prolonged, C(max) was increased, and AUC(0-∞) was raised. Of the 55 evaluable patients, 7 patients experienced partial responses, including 5 with breast cancer, 1 with lung cancer, and 1 with gastric cancer. The best response with stable disease for ≥ 6 months was achieved in 7 patients. CONCLUSIONS: Based on the DLT and PK profile, the RP2D was defined as 1000 mg TID with evidence of preliminary anti-tumor activity. Further studies are recommended.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Allitinib effectively inhibits the EGFRT790M/L858R double mutant with an IC50 value of 12 nM.
“Allitinib effectively inhibits the EGFRT790M/L858R double mutant with an IC50 value of 12 nM.177–181”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [179]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · see citing works
<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871 · see citing works
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517 · see citing works
Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617 · see citing works
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447 · see citing works
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A. C., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 823 · see citing works
Engelman, J. A., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 706 · see citing works
Hecht, J. R., Bang, Y., Qin, S., Chung, H. C., Xu, J., Park, J. O., Jeziorski, K., Shparyk, Y. V., Hoff, P. M., Sobrero, A. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6598 · Cited by 624 · see citing works
Self-citationSatoh, T., Xu, R., Chung, H. C., Sun, G., Doi, T., Xu, J., Tsuji, A., Omuro, Y., Li, J., Wang, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6136 · Cited by 622 · see citing works
Self-citationBurris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K., O’Neil, B. H., Marcom, P. K., Ellis, M. J., Overmoyer, B. A., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619 · see citing works
Targeting the ERBB family in cancer: couples therapy
Tebbutt, N. C., Pedersen, M. W., & Johns, T. G. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3559 · Cited by 464 · see citing works
Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7278 · Cited by 349 · see citing works
Wong, K.-K., Fracasso, P. M., Bukowski, R. M., Lynch, T. J., Münster, P. N., Shapiro, G. I., Janne, P. A., Eder, J. P., Naughton, M. J., Ellis, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1978 · Cited by 301 · see citing works
Lin, N., Winer, E. P., Wheatley, D. A., Carey, L., Houston, S. J., Mendelson, D. S., Münster, P. N., Frakes, L., Kelly, S., García, A. A., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2003-y · Cited by 195 · see citing works
Iqbal, S., Goldman, B. H., Fenoglio‐Preiser, C. M., Lenz, H., Zhang, W., Danenberg, K. D., Shibata, S., & Blanke, C. D. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr021 · Cited by 158 · see citing works
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Pérez-Soler, R. (2003) · PubMed · Cited by 151 · see citing works
Single-Dose Clinical Pharmacokinetic Studies of Gefitinib
Swaisland, H., Smith, R. P., Laight, A., Kerr, D. J., Ranson, M., Wilder‐Smith, C. H., & Duvauchelle, T. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544110-00004 · Cited by 142 · see citing works
Hecht, J. R., Bang, Y., Qin, S., Chung, H.-C., Xu, J., Park, J. O., Jeziorski, K., Shparyk, Y. V., Hoff, P. M., Sobrero, A. F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.lba4001 · Cited by 127 · see citing works
Self-citationJoensuu, H., Kellokumpu‐Lehtinen, P., Huovinen, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4639 · Cited by 117 · see citing works
Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva)
Hidalgo, M. M., & Bloedow, D. C. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70012-8 · Cited by 99 · see citing works
Takahashi, T., Boku, N., Murakami, H., Naito, T., Tsuya, A., Nakamura, Y., Ono, A., Machida, N., Yamazaki, K., Watanabe, J., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9789-z · Cited by 64 · see citing works
Bang, Y. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.4_suppl.11 · Cited by 56 · see citing works
Ito, Y., Suenaga, M., Hatake, K., Takahashi, S., Yokoyama, M., Onozawa, Y., Yamazaki, K., Hironaka, S., Hashigami, K., Hasegawa, H., et al. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys012 · Cited by 54 · see citing works
Xie, H., Lin, L., Tong, L., Jiang, Y., Zheng, M., Chen, Z., Jiang, X., Zhang, X., Ren, X., Qu, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021487 · Cited by 48 · see citing works
Self-citationMarshall, J. L., Hwang, J., Eskens, F. A. L. M., Burger, H., Malik, S. M., Uttenreuther‐Fischer, M., Stopfer, P., Ould-Kaci, M., Cohen, R. B., & Lewis, N. L. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9890-y · Cited by 46 · see citing works
Gordon, M. S., Mendelson, D. S., Gross, M. E., Uttenreuther‐Fischer, M., Ould-Kaci, M., Zhao, Y., Stopfer, P., & Agus, D. B. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9904-9 · Cited by 37 · see citing works
Tjulandin, S. A., Moiseyenko, V. M., Семиглазов, В. В., Manikhas, G. M., Learoyd, M., Saunders, A., Stuart, M., & Keilholz, U. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9963-6 · Cited by 25 · see citing works
Hecht, J. R., Cohn, A. L., Dakhil, S. R., Saleh, M. N., Piperdi, B., Cline-Burkhardt, V. J. M., Tian, Y., & Go, W. Y. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.4_suppl.454 · Cited by 21 · see citing works
PG 10.04 Adjuvant chemotherapy: an option for Asian patients only?
Bang, Y.-J. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)70034-5 · Cited by 8 · see citing works
Kohli, M., Oberg, A. L., Mahoney, D. W., Riska, S. M., Zhang, Y., Zenka, R. M., Sahasrabudhe, D. M., Qin, R., Carlson, R. E., & Zhang, S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.30_suppl.11 · Cited by 4 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
EGFR-TKIs resistance via EGFR-independent signaling pathways
Liu, Q., Yu, S., Zhao, W., Qin, S., Chu, Q., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0793-1 · Cited by 413 · see citing works
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Yuan, X., Wu, H. K., Han, N., Xu, H., Chu, Q., Yu, S., Chen, Y., & Wu, K. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0087-z · Cited by 245 · see citing works
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 217 · see citing works
Strategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 111 · see citing works
Schroeder, R. L., Stevens, C. L. K., & Sridhar, J. (2014) · Molecules · doi:10.3390/molecules190915196 · Cited by 101 · see citing works
Emerging therapeutic agents for lung cancer
Dholaria, B., Hammond, W. A., Shreders, A. J., & Lou, Y. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0365-z · Cited by 91 · see citing works
Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
Sun, W., Yuan, X., Tian, Y., Wu, H. K., Xu, H., Hu, G., & Wu, K. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0193-6 · Cited by 86 · see citing works
CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer
Xu, H., Wu, K., Tian, Y., Liu, Q., Han, N., Yuan, X., Zhang, L., Wu, G. S., & Wu, K. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3639 · Cited by 74 · see citing works
A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors
El–Gamal, M. I., Mewafi, N. H., Abdelmotteleb, N. E., Emara, M. A., Tarazi, H., Sbenati, R. M., Madkour, M. M., Zaraei, S., Shahin, A. I., & Anbar, H. S. (2021) · Molecules · doi:10.3390/molecules26237376 · Cited by 72 · see citing works
Wang, Y., Zhang, Y., Kathawala, R. J., & Chen, Z. (2014) · Cancers · doi:10.3390/cancers6041925 · Cited by 62 · see citing works
Self-citationOliveira, R. J. D. S., Silva, V. A. O., Martinho, O., Cruvinel‐Carloni, A., Melendez, M. E., Rosa, M. N., de Paula, F. E., Viana, L. D. S., Carvalho, A. L., & Reis, R. M. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0270-z · Cited by 45 · see citing works
Distinct genetic alterations in small cell carcinoma from different anatomic sites
Zheng, X., Liu, D., Fallon, J. T., & Zhong, M. (2015) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-4-2 · Cited by 40 · see citing works
AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors
Oliveira, R. J. D. S., Melendez, M. E., Martinho, O., Zanon, M. F., Viana, L. D. S., Carvalho, A. L., & Reis, R. M. (2017) · Oncotarget · doi:10.18632/oncotarget.18395 · Cited by 38 · see citing works
Hypoxia/lncRNA-AK123072/EGFR pathway induced metastasis and invasion in gastric cancer.
Yang, Z., Wang, R., Zhang, T., & Dong, X. (2015) · PubMed Central · Cited by 35 · see citing works
Knockdown of EGFR inhibits growth and invasion of gastric cancer cells
Zhen, Y., Guanghui, L., & Xiefu, Z. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.55 · Cited by 33 · see citing works
Muthusami, S., Sabanayagam, R., Periyasamy, L., Bharathi, M., & Park, W. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.117 · Cited by 31 · see citing works
Ruoming, W., Zhen, Y., Tengteng, Z., & Jisheng, H. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.41 · Cited by 27 · see citing works
RetractedOptofluidic device for the quantification of circulating tumor cells in breast cancer
Pedrol, È., García‐Algar, M., Massons, J., Nazarenus, M., Guerrini, L., Martínez, J., Ródenas, A., Fernandez-Carrascal, A., Aguiló, M., García‐Estévez, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04033-9 · Cited by 27 · see citing works
Chen, Z., Liu, S., Xia, Y., & Wu, K. (2016) · Medical Science Monitor · doi:10.12659/msm.898399 · Cited by 21 · see citing works
Self-citationLi, T., Piperdi, B., Walsh, W. V., Kim, M., Beckett, L. A., Gucalp, R. A., Haigentz, M., Bathini, V. G., Wen, H., Zhou, K., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.10.003 · Cited by 18 · see citing works
Daniele, S., Barresi, E., Zappelli, E., Marinelli, L., Novellino, E., Settimo, F. D., Taliani, S., Trincavelli, M. L., & Martini, C. (2016) · Oncotarget · doi:10.18632/oncotarget.6872 · Cited by 18 · see citing works
Tang, Q., Peng, T., Hu, J., Zhang, T., Chen, P., Chen, D., Wang, Y., Chen, L., Tong, L., Chen, Y., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114249 · Cited by 16 · see citing works
Bhagyalalitha, M., Akshatha, H. S., Kumar, S. A., Singh, M., Pujar, K. G., Bidye, D. P., & Pujar, G. V. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107695 · Cited by 14 · see citing works
Qiang, Z., Wan, J., Chen, X., & Wang, H. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-837 · Cited by 13 · see citing works
ERBB4 selectively amplifies TGF-β pro-metastatic responses
Luo, P., Hong, H., Zhang, B., Li, J., Zhang, S., Yue, C., Cao, J., Wang, J., Dai, Y., Liao, Q., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115210 · Cited by 11 · see citing works
Self-citationOliveira, R. J. D. S., Gomes, I. N. F., da Silva, L. S., Lengert, A. V. H., Laus, A. C., Melendez, M. E., Munari, C. C., Cury, F. D. P., Longato, G. B., & Reis, R. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147774 · Cited by 10 · see citing works
O’Neill, C. E., Sun, K., Sundararaman, S., Chang, J. C., & Glynn, S. A. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1358850 · Cited by 7 · see citing works
Advances in Small-molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-cancer Agents
Kang, J.-X., Li, C., Cheng, Y.-M., Huang, M.-X., Zhao, G.-K., Jin, Z., Qi, X., Gu, J., & Ouyang, Q. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673308896240528173317 · Cited by 6 · see citing works
Pithi Chanvorachote, B., & Chunhacha, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804003-4.00004-9 · Cited by 6 · see citing works
Kamarehei, F., Saidijam, M., & Taherkhani, A. (2023) · Genomics & Informatics · doi:10.5808/gi.22072 · Cited by 5 · see citing works
Wang, G.-D., Liu, L., Zhao, Y., Lin, Y.-L., & Er, L. (2025) · Medicine · doi:10.1097/md.0000000000040332 · Cited by 3 · see citing works
Shukla, S., Patel, A. S., & Ambudkar, S. V. (2015) · Springer eBooks · doi:10.1007/978-3-319-23476-2_10 · Cited by 3 · see citing works
Arantes, L. M. R. B., Oliveira, R. J. D. S., de Carvalho, A. C., Melendez, M. E., Sorroche, B. P., Teixeira, R. D. J., Tostes, K., Palmero, E. I., Reis, R. M., & Carvalho, A. L. (2023) · Head & Neck · doi:10.1002/hed.27602 · Cited by 2 · see citing works
Suryawanshi, M. V., Girase, R. T., Bagul, V. S., & Gujarathi, P. P. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04331-7 · Cited by 2 · see citing works
Ruoming, W., Zhen, Y., Tengteng, Z., & Jisheng, H. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00325-5 · Cited by 2 · see citing works
RetractedBustos-Carpinteyro, A. R., Magaña‐Torres, M. T., González-García, J. R., Torres-Jasso, J. H., & Sánchez-López, J. Y. (2017) · Gaceta Médica de México · doi:10.24875/gmm.17002748 · Cited by 1 · see citing works
Egfr: An Important Perspective in Cancer Therapy
Shahare, H. V., & Gokul, S. (2019) · Research Journal of Life Sciences Bioinformatics Pharmaceutical and Chemical Sciences · doi:10.26479/2019.0502.11 · Cited by 1 · see citing works
Bustos-Carpinteyro, A. R., Magaña‐Torres, M. T., González-García, J. R., Torres-Jasso, J. H., & Sánchez-López, J. Y. (2018) · Gaceta Médica de México · doi:10.24875/gmm.m18000090
Liu, G., Xue, J., Wang, Y., Liu, Z., Li, X., Qu, D., Su, Z., Xu, K., Qu, X., Qu, Z., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04148-1
- Authors
- Zhang, J., Cao, J., Li, J., Zhang, Y., Chen, Z., Peng, W., Sun, S., Zhao, N., Wang, J., Zhong, D., Zhang, X., & Zhang, J.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Chinese Academy of Sciences (CN)
- Fudan University (CN)
- Corresponding author
- Cao, Junning
- Li, Jin
- Venue
- Journal of Hematology & Oncology
- Published
- 2014-03-11
- Volume
- 7
- Issue
- 1
- Pages
- 22-22
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC4007625
- OpenAlex
- W2115682164
- Cited by
- 40
- References
- 32
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 3 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 5 · 2014: 5
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gastric Cancer Management and Outcomes
- Keywords
- irreversible kinase inhibitors, EGFR, HER2, ErbB4, advanced solid tumors, dose-limiting toxicity, diarrhea, pharmacokinetics, food effect on absorption, oral administration, breast cancer, lung cancer, gastric cancer, anticancer activity, dose escalation, safety and tolerability, recommended phase 2 dose, maximum tolerated dose, partial response, stable disease
- MeSH terms
- Acrylamides, Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Neoplasms, Quinazolines, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Young Adult, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
